Join the club for FREE to access the whole archive and other member benefits.

Reason reports back from October's Rejuvenation Startup Summit

Some really exciting developments with quite a few in clinical trials


Key points from article :

Was much more focused on the industry rather than on scientific programs.

Eric Verdin (Buck Institute)

 - discussed recent work on biomarkers of aging, specifically epigenetic clocks 

 - different immune cell populations exhibit sizable differences in assessed epigenetic age

 - also differences based on infection and inflammation status

Lou Hawthorne (Nanotics)

 - platform produces particles that bind to, and deplete, specific molecules in the blood stream

 - could target and remove harmful factors from aged blood

 - focused on pro-inflammatory factors - initially the cytokine storm of sepsis

Alexander Schueller (cellvie)

 - discussed mitochondrial dysfunction observed in aging

 - aims to generate and deliver replacement allogeneic mitochondria

 - first indication for clinical development is sarcopenia

Vlad Vitoc (Maia Biotechnology)

 - working towards a near-universal cancer therapy based on delivery of THIO

 - THIO is metabolised and utilized by telomerase, which nearly all cancer cells aggressively utilize

 - have phase 1 clinical trials running now and more planned

 - trials are conducted in partnership with Regeneron's checkpoint inhibitor therapy

Chris Rinsch (Amazentis)

 - urolithin A supplement for improving mitochondrial function in aged individuals

 - believe it works by improving both mitophagy and mitochondrial biosynthesis

Dobri Kiprov (Lyfspn)

 - presented a range of human data from therapeutic plasma exchange patients

 -  various benefits seen - believed to be driven by modulation of the immune system

 - unable, yet, so say how long the benefits last from one treatment.

Pankaj Kapahi (Juvify)

 - supplement is a modulator of glycation

 - hypothesis is that the generation of advanced glycation endproducts (AGEs) is the major problem that is produced by sugar metabolism

 - short-lived AGEs are acting as appetite enhancers so benefits may be from calorie restriction

Yuri Deigin (Youth Bio)

 - presented partial reprogramming findings in mice

 - as well as using OSKM factors it is looking for novel factors with tissue-specificity

 - mice tend to die when liver and intestine are repeatedly reprogrammed

 - initial indication is Alzheimer's disease using periodic activation of altered genes

Silke Hüttner (Rejuvenate Biomed)

 - combinatorial therapies using small molecules

 - initially focused on how inflammation affects sarcopenia

Mourad Topors (Repair Biotechnologies)

 - using gene and cell therapies to break down excess intracellular free cholesterol

 - finding a faster path to the clinic in treatment of nonalcoholic steatohepatitis (NASH)

 - raising funds to start clinical development program leading to human trials

Robin Mansukhani (Deciduous Therapeutics)

 - using small molecules to train invariant natural killer cells to attack senescent cells

 - one-time treatment rouses immune cells for at least months thereafter

Mike Kope (Cyclarity)

 - employs engineered cyclodextrins to bind 7-ketocholesterol to treat atherosclerosis

 - they can reverse the foam cell state that arises from 7-ketocholesterol exposure

 - will begin their first clinical trials next year

Cristiana Banila (Mitra Bio)

 - developed a way to measure epigenetic age in skin non-invasively

 - skin cells obtained with adhesive tape have same results as those obtained using biopsies

Brian Kennedy (National University of Singapore)

 - run 6-9 month interventions in mice and healthy older people while assessing biomarkers

 - mainly looking at well-known small molecule geroprotectors (e.g. rapamycin)

 - automation allows tens of thousands of experiments, using combined therapies, in nematode worms

Chris Shepard (Thymofox)

 - highlighted that a young thymus is able to regenerate from injury

 - looking for factors (upstream of FOXN1) that regulate the decline of the ability with age

Mark Allen (Elevian)

 - outline  their work on GDF11

 - selected stroke recovery as the first clinical indication

 - in mice recombinant GDF11 promotes vascular regeneration, activates stem cells, suppresses inflammation and improves metabolism

 - first clinical trial for stroke recovery will begin in 2023

Matthias Breugelmans (Elastrin Therapeutics)

 - regeneration of damaged elastin fibers in the extracellular matrix

 - employs an albumin nanoparticle decorated with antibodies that bind to damaged elastin

 - targeting a variety of indications, including vascular calcification, aneurysm and hypertension

Matthew Rosen (CoRegen)

 - regulatory T-cell (Treg) based approach to defeating many different types of cancer

 - gene knockdown of SRC-3 in Tregs may prevent solid tumors subverting the immune system by co-opting Treg cells

 - aiming at a first phase 1 in 2023

Peter Fedichev (Gero)

 - using AI to characterize degenerative aging into two different processes: damage and loss of resilience

 - balance between these is different in mice and humans - hence most small molecules will have little effect in  humans

Aaron Cravens (Revel Pharmaceuticals)

 - developing a platform for high throughput enzyme engineering

 - still working on enzymes to break glucosepane, CML, and other cross-links involved in aging

 - intend to raise a series A next year

Hans S. Keirstead (Immunis)

 - harvest the secretome of progenitor cell lines as a therapeutic product

 - helps with sarcopenia, fibrosis, inflammation, arterial stiffness and adaptive immunity

Robert Cargill (Glionics)

 - engineered microglia to deliver therapeutic molecules throughout the brain

 - have demonstrated repopulation following clearance in mice

Rob Konrad Maciejewski (Biolytica)

 - outlined a vision for data-driven approach to personalized medicine and lifestyle changes

Joshua McClure (Maxwell Biosciences )

 - drug discovery platform producing stable variations of an antimicrobial peptide

 - effective against pathogens of many types, including fungi, bacteria, and viruses

 - could be a replacement for existing antibiotics and antivirals

Sophie Chabloz (Avea)

 - supplement company offering NAD+ upregulation formulations incorporating nicotinamide mononucleotide

Felix Frueh (PAGE Therapeutics)

 - targeting metastasis in cancer therapy

 - only clusters of, not solitary, circulating tumor cells produce metastasis

Jürgen Reeß (Mogling Bio)

 - restoration of immune function in older individuals using derivatives of CASIN to inhibit CDC42

 - very early-stage company with promising mouse data

Mentioned in this article:

Click on resource name for more details.

Aaron Cravens

Bioengineer and CEO at Revel Pharmaceuticals

Alex Schueller

Founder and CEO at Cellvie


Company focused to clinical development of naturally derived bioactives.


Science-based and personalized longevity supplements, ensuring long-lasting life


Increasing human healthspan and performance through state-of-the-art health data analytics

Brian Kennedy

Prof of Biochemistry and Physiology at NUS, CSO Ponce De Leon Health

Buck Institute

Independent biomedical research institute focused on aging


Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell

Chris Rinsch

CEO and Co-Founder of Amazentis

Chris Shepard

Founder and CEO at Avogadro, Medical Scientist and Venture Partner at Apollo Health Ventures

Cristiana Banila

Molecular biologist, Co-founder and CSO at Mitra Bio

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.

Deciduous Therapeutics

Company developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.

Dobri Kiprov

Co-founder and Chief Medical Officer of Lyfspn

Elastrin Therapeutics

South Carolina-based biotech developing novel therapies


Young blood medicine maker for body rejuvenation.

Eric Verdin

CEO & President at Buck Institute for Research on Aging

Felix Frueh

xpert in Precision Medicine, Entrepreneur, Co-founder and CSO at Selva Therapeutics


AI-powered platform for drug discovery and drug repurposing for age-related diseases.

Hans Keirstead

Chairman and Chief Executive Officer at AIVITA Biomedical and Chairman of the Board at Immunis


Biotechnology company changing the course of immune-related diseases and ageing

Joshua McClure

Founder, CEO and Chairman at Maxwell Biosciences

Juergen Reess

Co-founder and CEO at Mogling Bio, Managing Director at Cellerys AG


Supplements company providing affordable, accessible and science-backed options for healthy living

Louis Hawthorne

Founder and CEO at NaNotics


Working to invent novel therapies that will allow us live longer, healthier lives.

MAIA Biotechnology

Company developing new drugs to help people with cancer.

Mark Allen

Co-Founder and CEO at Elevian

Matthias Breugelmans

Life science entrepreneur and CEO of Elastrin Therapeutics

Maxwell Biosciences

Biotechnology company focused on the treatment of infectious diseases

Michael Kope

Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals

Mitra Bio

Company building a non-invasive skin multi-omics platform to unravel skin health and delay ageing

Mogling Bio

Biopharmaceutical company developing new treatments for rejuvenating old stem cells

Mourad Topors

Chief Scientific Officer of Repair Biotechnologies


Company developing a novel nano-medicine platform for treating multiple diseases, including cancer, sepsis, auto-immune disorders and the harmful effects of aging.

National University of Singapore (NUS)

Asia’s leading university with a global approach in education, research and service.

Pankaj Kapahi

Education professional skilled in Research, Life Sciences, Genetics, Biochemistry, and Science

Peter Fedichev

Founder of Gero and physicist in drug discovery land

Rejuvenate Biomed

Biomedical company researching the biology of aging and developing drugs for age related diseases.

Rejuvenation Startup Summit 2022

14-Oct-2022 to 15-Oct-2022

The leading networking event for rejuvenation startups, longevity investors and translational researchers by Forever Healthy Foundation

Repair Biotechnologies

Biotechnology company focused on developing drugs for cholesterol and aging-related diseases

Revel Pharmaceuticals

Biotechnology company commercializing therapeutic enzymes to degrade age associated molecule damage.

Rob Konrad Maciejewski

CEO and Co-Founder at Biolytica

Robert S. Cargill

Health technology entrepreneur working to accelerate advances in regenerative medicine

Robin Mansukhani

CEO and Co-founder of Deciduous Therapeutics

Silke Hüttner

Chief Medical Officer at Rejuvenate Biomed

Sophie Chabloz

Co-Founder and CPO at Avea Life

Vlad Vitoc

Founder and CEO at MAIA Biotechnology

YouthBio Therapeutics

Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors

Yuri Deigin

Co-founder and Director at YouthBio Therapeutics

Topics mentioned on this page:
Ageing Research
Reason reports back from October's Rejuvenation Startup Summit